FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2028-2039 November 15, 2007 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Purchase this article Editorial by Sambrook, P. N. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.

Methods In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 µg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety.

Results At the last measurement, the mean (±SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2±0.7% vs. 3.4±0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.

Conclusions Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov] .)

Source Information

From the University of Alabama at Birmingham, Birmingham (K.G.S.); College of Physicians and Surgeons, Columbia University, New York (E.S.); Katholieke Universiteit Leuven, Leuven, Belgium (S.B.); and Lilly Research Laboratories, Eli Lilly, Indianapolis (F.M., D.W.D., K.A.T., G.P.D., R.M.).

Address reprint requests to Dr. Saag at the University of Alabama at Birmingham, FOT 820, 1530 Third Ave. S., Birmingham, AL 35294-3408, or at ksaag{at}uab.edu.

Full Text of this Article

Related Letters:

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Rossi C. M., Di Comite G., Babb R. R., Nori U. S., Agarwal A. K., Rovin B. H., Saag K. G., Shane E., Marcus R.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1302-1304, Mar 20, 2008. Correspondence

This article has been cited by other articles:

• Tilg, H, Moschen, A R, Kaser, A, Pines, A, Dotan, I (2008). Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694 [Abstract] [Full Text]  
• Clay, P. G, Voss, L. E, Williams, C., Daume, E. C (2008). Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons. The Annals of Pharmacotherapy 42: 670-679 [Abstract] [Full Text]  
• Rossi, C. M., Di Comite, G., Babb, R. R., Nori, U. S., Agarwal, A. K., Rovin, B. H., Saag, K. G., Shane, E., Marcus, R. (2008). Teriparatide or alendronate in glucocorticoid-induced osteoporosis.. NEJM 358: 1302-1303 [Full Text]  
• Stroup, J., Kane, M. P., Abu-Baker, A. M. (2008). Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65: 532-539 [Abstract] [Full Text]  
• (2007). Parathyroid Hormone vs. Alendronate for Steroid-Induced Osteoporosis. JWatch General 2007: 2-2 [Full Text]  
• Sambrook, P. N. (2007). Anabolic Therapy in Glucocorticoid-Induced Osteoporosis. NEJM 357: 2084-2086 [Full Text]  
• (2007). Biologic Therapy Apparently More Effective Than Oral Therapy for Glucocorticoid-Associated Osteoporosis. Journal Watch Dermatology 2007: 1-1 [Full Text]